FindProfit.com Investigates the Investment Implications of the Avian Bird Flu

Date : 10/31/2005 @ 12:23PM
Source : PR Newswire
Stock : Hemispherx Biopharma, (HEB)
Quote : 0.7798  -0.0497 (-5.99%) @ 1:18PM
<< BackQuote Chart Financials

 

FindProfit.com Investigates the Investment Implications of the Avian Bird Flu

PRINCETON, N.J., Oct. 31 /PRNewswire/ --

FindProfit (http://www.findprofit.com/), an investment service that delivered an +18% average return in 2004 and is up an average of 9.1% through October 2005, invites investors to learn how to stress test their portfolios against the bird flu.

"Just as we worry about the housing bubble, the trade deficit, or the bird flu today, investors have always found something to worry about. In fact, these worries have often led to the best investment opportunities for those with a level head and capital in reserve," FindProfit.com Editor, Bill Martin writes in "How To Stress Test Your Portfolio Against The Bird Flu."

Martin teaches investors how to prepare for potentially world-impacting events such as the H5N1 flu, commonly known as the Avian Bird Flu. Among other strategies, Martin notes that "flu favorites" such as Sinovac (AMEX:SVA), Novavax (NASDAQ:NVAX) and Hemispherx Biopharma (AMEX:HEB) don't have "staying power," while investors need to look beyond the flu when examining heavyweights such as GlaxoSmithKline (NYSE:GSK).

Sign up now for a 30-day free trial to FindProfit and gain instant access to FindProfit's in-depth coverage of the media, tech, telecom, financial, pharmaceutical and energy sectors, as well as our full investment commentary and comprehensive model portfolios, by clicking here: https://www.findprofit.com/subscribe/?refer=prnew1 .

FindProfit finds you winners and has beaten the market three years in a row. The service posted average model portfolio returns of 53.4% in 2003, 18.6% in 2004, and 9.1% through October 2005. This compares to average returns in the three major market indexes of 33.9% in 2003, 6.89% in 2004, and -2.1% through October 2005. All portfolio returns have been validated by a Certified Public Accounting firm.

About FindProfit.com:

FindProfit.com is a leading publisher of timely and actionable investment commentary for both individual and institutional investors. FindProfit's investment service gives investors the edge they need to consistently beat the market. For more information or to sign up now for a free 30-day trial to FindProfit, please visit: https://www.findprofit.com/subscribe/?refer=prnew1 .

NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcie Martin, FindProfit, +1-888-440-6116

DATASOURCE: Indie Research Advisors, LLC

CONTACT: Marcie Martin, FindProfit, +1-888-440-6116

Web site: http://www.findprofit.com/


Hemispherx Biopharma, Historical Chart Hemispherx Biopharma, Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
The Spread Bet Centre :: The CFD Centre :: Financial Glossary :: Forex Rates, Charts & News
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright 1999-2010 ADVFN PLC. Copyright Notice & Privacy Policy :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
31 site:2us 100312 13:36